Financial Performance Summary

Consolidated Financial Results (₹ Crores):

| Particulars | Q1 FY27 | Q1 FY26 | YoY Growth | FY26 Annual |

| Revenue from Operations | 470.9 | 351.5 | 34.0% | 1,630.0 |

| EBITDA | 75.1 | 56.6 | 32.7% | 250.3 |

| EBITDA Margin | 16.0% | 16.1% | (10 bps) | 15.4% |

| PAT | 44.1 | 31.0 | 42.3% | 140.9 |

| PAT Margin | 9.4% | Not specified | Not specified | Not specified |

Key Performance Highlights

Q1 FY27 vs. Q1 FY26 Performance:

  • Revenue from Operations registered strong growth of 34.0% to ₹470.9 crores from ₹351.5 crores
  • EBITDA growth of 32.7% to ₹75.1 crores from ₹56.6 crores
  • EBITDA margin for the quarter was 16.0%, slightly down by 10 basis points from 16.1% in Q1 FY26
  • PAT for the quarter was ₹44.1 crores, registering growth of 42.3%
  • PAT margin was 9.4% for the quarter

Business Model and Operational Context

The company operates across the entire pharmaceuticals value chain including:

  • Research and development
  • Manufacturing
  • Distribution
  • Marketing
  • Exports

Business Segments:

1. CDMO Services & Products: Provides pharmaceutical products to over 350 clients in India and key international markets

2. Branded Generics Business: Strong direct presence across India and international markets

Manufacturing Infrastructure:

  • Five state-of-the-art manufacturing facilities consisting of 9 independent blocks
  • Accredited by leading global regulatory bodies: WHO-GMP, EU-GMP, UK-MHRA, PIC/s
  • Jammu facility is witnessing a steady ramp-up with increasing business from existing customers and onboarding of new clients

Management Commentary

Mr. Vinay Lohariwala, Managing Director, commented on the performance:

  • Delivered strong start to FY27 with revenue and EBITDA growing by 34% and 33% YoY respectively
  • Performance underscores continued strength of diversified business model, disciplined execution, and sustained customer traction
  • Growth supported by steady order flows, broader product portfolio, and deeper engagement with existing and new customers
  • Focus on operational excellence, manufacturing efficiency, and quality strengthens competitive positioning
  • Enables meeting evolving requirements of domestic and international markets
  • Committed to strengthening position as trusted CDMO partner while expanding branded generics footprint
  • Confident of sustaining growth with clear strategic roadmap, disciplined capital allocation, and timely execution

Forward Outlook

  • Focus on enhancing profitability and delivering long-term value for stakeholders
  • Continued expansion across key markets
  • Maintenance of operational excellence and manufacturing efficiency